US stock futures flounder amid tech weakness, Fed caution
HONG KONG - HUTCHMED (China) Limited (NASDAQ/AIM: HCM; HKEX:13), a biopharmaceutical company, has announced that it will disclose its final financial results for the year ended December 31, 2024, on Wednesday, March 19, 2025. The announcement will be made at 7:00 am EDT, followed by a live conference call and audio webcast presentation for analysts and investors.
The company, known for its discovery and development of targeted therapies and immunotherapies for cancer and immunological diseases, has invited interested parties to attend the English language conference call and Q&A session, which will occur at 8:00 am EDT on the same day. Additionally, a Chinese (Putonghua) webcast is scheduled for 8:30 pm EDT on Wednesday, March 19, 2025. Both webcasts will be accessible via HUTCHMED’s website, where the presentation will also be available for download prior to the conference call.
HUTCHMED has been actively marketing its first three medicines in China, with one also approved in the United States, Europe, and Japan. The company’s commitment to bringing drug candidates from in-house discovery to patients globally has been a cornerstone of its strategy.
Details for the conference call dial-in will be provided in the financial results announcement and on the company’s website. A replay of the event will be available on the website shortly after the live presentation concludes.
This upcoming financial results announcement is based on a press release statement and will provide investors and analysts with an opportunity to review HUTCHMED’s performance over the past year. The company’s progress in commercializing its treatments and expanding its global reach will be key points of interest during the presentation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.